Ocugen found using ticker (OCGN) have now 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 1 and 0.7 with the average target price sitting at 0.9. Given that the stocks previous close was at 0.29 this would indicate that there is a potential upside of 210.3%. There is a 50 day moving average of 0.31 and the 200 day moving average is 0.34. The market cap for the company is $130m. Visit the company website at: http://www.ocugen.com
Ocugen, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company’s pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.